Combination of MiR-378 and MiR-210 Serum Levels Enables Sensitive Detection of Renal Cell Carcinoma

International Journal of Molecular Sciences

Michal Fedorko¹  Michal Stanik²  Robert Iliev³  Martina Redova-Lojova⁴  Tana Machackova⁴  Marek Svoboda³  Dalibor Pacik¹  Jan Dolezel²  Ondrej Slaby³ 

[1] Department of Urology, University Hospital Brno and Masaryk University Brno, Brno 62500, Czech Republic; E-Mails:;Department of Urologic Oncology, Masaryk Memorial Cancer Institute, Brno 65653, Czech Republic; E-Mails:;Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno 65653, Czech Republic; E-Mails:;Central European Institute of Technology, Masaryk University, Brno 62500, Czech Republic; E-Mails:

关键词: renal cell carcinoma;    microRNA;    blood serum;    biomarker;   

DOI  :  10.3390/ijms161023382

来源: mdpi

【 摘 要 】

Serum microRNAs are emerging as a clinically useful tool for early and non-invasive detection of various cancer types including renal cell carcinoma (RCC). Based on our previous results, we performed the study to analyze circulating serum miR-378 and miR-210 in patients with various histological subtypes of RCC. RNA was purified from blood serum samples of 195 RCC patients and 100 healthy controls. The levels of miR-378 and miR-210 in serum were determined absolutely using quantitative real-time PCR. Pre- and postoperative levels of both microRNAs were compared in 20 RCC patients. Significantly increased serum levels of both miR-378 and miR-210 enabled to clearly distinguish RCC patients and healthy controls with 80% sensitivity and 78% specificity if analyzed in combination (p < 0.0001), and their levels significantly decreased in the time period of three months after radical nephrectomy (p < 0.0001). Increased level of miR-378 positively correlates with disease-free survival (p = 0.036) and clinical stage (p = 0.0476). The analysis of serum miR-378 and miR-210 proved their potential to serve as powerful non-invasive diagnostic and prognostic biomarkers in RCC.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.